294 results about "Sequence identity" patented technology

The invention relates to a recombinant I-type humanized collagen with crosslinking property as well as a preparation method and application thereof, and belongs to the technical field of recombinant proteins. The invention relates to recombinant I-type humanized collagen with crosslinking property. The amino acid sequence of the recombinant I-type humanized collagen comprises an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence with the sequence identity of more than 90% with the sequence as shown in SEQ ID No.1; the recombinant I-type humanized collagen has a triple helix structure. A complete triple helix structure can be efficiently expressed, and the hydrogel has efficient cross-linking capability, so that the hydrogel can be efficiently and stably formed through cross-linking.

The invention relates to a recombinant elastin and a preparation method thereof as well as a recombinant elastin raw material and application thereof, and belongs to the technical field of recombinant proteins. The amino acid sequence of the recombinant elastin is an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence of which the sequence identity with the SEQ ID No.1 is more than 90%. The protein is high in expression level, high in purity and relatively high in biological activity, and has the effects of supplementing skin collagen, resisting aging and repairing skin barriers.

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and / or booster vaccination in a subject.

The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.

Variants having cutinase activity of a parent cutinase, the variants comprising alterations at one or more (e.g., several) positions corresponding to positions 181, 182, 115, 161, 1, 2, 43, 55, 79, or 5 of SEQ ID NO: 2, where the alterations are substitutions for positions 181, 115, 161, 43, 55, 79, and 5, and deletions for positions 1, 2, and 182, and where the variants have at least 75% but less than 100% sequence identity to a mature polypeptide of SEQ ID NO: 2. Polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells including the polynucleotides; as well as methods for obtaining the variants and methods for producing the variants. Comprising the variants, and methods for using the variants.

The present invention relates to immunoglobulin single variable domains (ISVDs) for the treatment of diseases by the enteral, e.g. oral, delivery. In particular, the present invention provides ISVDs comprising sequences with a high percentage of sequence identity to SEQ ID NO: 1 for such enteral administration. Such sequences were identified as extraordinarily stable in the gastrointestinal tract, which prevents their degradation and thereby allows them to exert a strong therapeutic effect.

The invention provides an isolated or engineered polynucleotide (10) comprising a coding sequence (12), wherein the coding sequence (12) encodes a protein (20), wherein an amino acid sequence of the protein (20) has at least 85% sequence identity with a reference amino acid sequence in a sequence alignment between the amino acid sequence and the reference amino acid sequence, wherein the reference amino acid sequence is selected from the group consisting of SEQ ID NO:8 11 14 1720, and wherein the protein (20) is a cannabinoid acid synthase (25).

A composition including a gene therapy delivery system and an alpha-galactosidase (GLA) polynucleotide encoding a GLA polypeptide, wherein the GLA polypeptide has at least 95% sequence identity to one of SEQ ID NOS. 1-40, 44-45, 51-52, 57, 61-173 or 212. Also provided are compositions, formulations, fusion proteins, and methods for the treatment of Fabry disease.

The present invention relates to a method for obtaining a detergent composition comprising introducing (a) a variant of a parent lipase having at least 60% sequence identity with SEQ ID NO:2, having a substitution at a position D254 of the mature polypeptide corresponding to SEQ ID NO:2, and having lipase activity; and (b) an anionic surfactant, wherein the composition has increased stability compared to a corresponding composition containing the parent lipase.

A variant polypeptide of xylanase, and a fusion protein and an enzyme composition comprising the variant polypeptide, a recombinant host cell for production of the variant polypeptide, methods for using it and its use, is disclosed comprising an amino acid sequence having at least 79%, but less than 100% amino acid sequence identity with amino acids 1-191 of SEQ ID NO: 1, wherein the amino acid sequence has xylanase activity, at least one disulfide bridge between two Cys residues in the 1-191 amino acid region, and an amino acid substitution at the position 23 or 28, or at the positions 23 and 28, the positions corresponding to the positions 23 and 28 of the SEQ ID NO: 1.

The present invention is directed to phage therapy for the treatment and control of bacterial infections, in particular urinary tract infections caused by Escherichia coli. More specifically, the present invention is directed to novel bacteriophage strains, cocktails thereof and variants thereof; and to methods using the same in the treatment, reduction or prevention of bacterial infections. The cocktail is used as a first line treatment against urinary tract infections, in particular in cancer patients, diabetic patients, or patients with a weakened immune system. Disclosed herein is a pharmaceutical composition comprising one or more purified strains of bacteriophage, each purified strain having a genome with at least 98% sequence identity to a nucleotide sequence selected from SEQ. ID No. 1, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 and / or variants thereof. The pharmaceutical composition may also be used in combination with other therapies for urinary tract infections such as antibiotics. The pharmaceutical composition may also be used in a method of diagnosis of the causative agent of a bacterial infection. A bacteriophage comprising at least 95% sequence identity with SEQ. ID No. 1, SEQ ID NO. 5 or SEQ ID NO. 6 is also disclosed.

The invention relates to the technical field of biological medicine, and relates to a polypeptide in targeted combination with SOX2 protein and application thereof, the polypeptide has an amino acid sequence as shown in SEQ ID NO.1, or has at least 85%, 90%, 95% or more than 99% of sequence identity with the amino acid sequence; the polypeptide inhibits phase separation of SOX2, liquid drops formed by phase separation of SOX2 can be avoided, then the situation that the liquid drops wrap chemotherapeutic drugs, influence the curative effect of the chemotherapeutic drugs and cause tolerance of tumor cells to the chemotherapeutic drugs is avoided, and the polypeptide does not influence the transcription activation function of SOX2 serving as a transcription factor; the polypeptide can inhibit the phase separation of the SOX2, so that the regulation of normal physiological functions, such as high expression in organs such as eyes of a human body, of the SOX2 as a transcription factor is not influenced, and therefore, the polypeptide disclosed by the invention can reverse chemotherapy drug resistance of tumors such as squamous carcinoma by inhibiting the phase separation of the SOX2, can be used for adjuvant therapy of the tumors such as squamous carcinoma, and has no obvious toxic or side effect on each organ of an organism.

The present invention relates to a composition ("TSP-DNA Oligo") comprising: a thermostable peptide ("TSP"), wherein the peptide comprises: an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4, or an amino acid sequence with at least about 92% sequence identity to a sequence as set forth in SEQ ID NO; 1, or SEQ ID NO: 2, or SEQ ID NO: 3 or SEQ ID NO: 4; and a "DNA Oligo" linked to the thermostable peptide through a linker, wherein the linker comprises: an azide group, an alkyne group, an isocyanate group, or a tetrazole group; wherein the "DNA oligo" comprises a promoter sequence for a T7, T3, SP6 RNA polymerase, or a known variant of said promoter sequence, or a sequence complementary to said promoter sequence or said variant.

The purpose of the present invention is to provide a novel mutant gene that imparts perpetual flowering properties to roses. Specifically, the present invention pertains to a KSN mutant gene comprising a base sequence (a) or (b): (a) a base sequence represented by SEQ ID NO: 1; and (b) a base sequence that is at least 90% identical in sequence to the base sequence represented by SEQ ID NO: 1, and maintains a transposon comprising the base sequence from position 729 to position 5812 in the base sequence represented by SEQ ID NO: 1.

In an aspect, provided is a DNA polymerase with an amino acid sequence of at least 80% sequence identity with SEQ ID NO: 1 and having one or more amino acid substitution, wherein the one or more amino acid substitution is selected from the group consisting of A83S, N91I, R96H, R96C, M97V, G108D, G111V, R113H, V118S, S122N, L126I, P127L, A134T, D145V, D145N, D147V, H149R, H149L, Q171L, Q171S, I173V, L178K, I179L, Q180M, F181L, K182D, D186T, G197S, D200K, S215P, K220N, V222I, W232Y, M336L, D341K, D341I, D341L, S349R, S349G, T368Y, D398I, V399R, Q560H, and any combination of two or more of the foregoing. Also provided are a kit including the polymerase, a polynucleotide encoding the polymerase, a method of synthesizing a polynucleotide using the polymerase, and a method of sequence a polynucleotide synthesized by the polynucleotide.

To provide a new agent for controlling soil-borne plant diseases, containing a microorganism as an active ingredient.SOLUTION: An agent for controlling a soil-borne plant disease, comprising, as an active ingredient, a Pseudomonad bacterium having a 16SrRNA genome comprising a nucleotide sequence having 96% or more sequence identity to a nucleotide sequence represented by SEQ ID NO: 1, a Pseudomonad bacterium having a 16SrRNA genome comprising a nucleotide sequence having 98% or more sequence identity to a nucleotide sequence represented by SEQ ID NO: 2, or a combination thereof.SELECTED DRAWING: None

The present invention relates to polynucleotide comprising a lncRNA gene according to SEQ ID No: 2, or according to a sequence having at least 50% sequence identity to SEQ ID No: 2, and an AP2c gene according to SEQ ID No: 3, or according to a sequence having at least 50% sequence identity to SEQ ID No: 3, which polynucleotide confers an increased density of type IV trichomes. The invention further relates to a plant comprising said polynucleotide and a SlASAT4 gene according to SEQ ID No. 21, or comprising a homologous sequence having at least 99.6% sequence identity to SEQ ID No. 21 wherein the presence of the polynucleotide leads to increased density of type IV trichomes and wherein the presence of said SlASAT4 gene leads to an increased ratio of S4:17 / S3:15 acyl sugars produced in glandular trichomes present on said plant when compared to a control plant lacking the polynucleotide and the SlASAT4 gene. Such a plant also was found to be resistant to Bemisia tabaci. The invention also discloses markers for the identification of the polynucleotide and the SlASAT4 gene and their use for the identification and development of Solanum lycopersicum plants. Also methods for identifying, producing and selecting of plants and seed are disclosed.

Data pipelines for string extraction, clustering, and comparison are disclosed. A method can include extracting sequence regions from each plasmid genome sequence sequenced from a genome of a plasmid based on presence of a fixed flanking sequence marker (FFSM) in the plasmid genome sequence. Each sequence region is within the FFSM and includes a candidate inverted terminal repeat (ITR) sequence. An example method further includes clustering two or more of the sequence regions based on perfect sequence identity to generate clusters; merging two or more of the clusters based on alignments between corresponding sequence regions of the two or more clusters; when a single cluster remains, identifying a genotype of a candidate ITR sequence of the single cluster based on local alignments; and using a plasmid having an ITR sequence with the genotype of the candidate ITR sequence to manufacture a plurality of AAV vectors based on the genotype of the candidate ITR sequence.

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

The present invention relates to fusarium toxin cleavage polypeptide variants of a fusarium toxin carboxylesterase having SEQ ID No.1, 46 wherein said polypeptide variants each have an amino acid sequence shortened by 47 amino acids at the N-terminus and said amino acid sequence has a sequence identity of at least 70%, preferably 80%, particularly preferably 100%, to the amino acid sequence segments 48-540 of SEQ ID No.46, i.e. SEQ ID No.1; and isolated polynucleotides encoding the polypeptide variants; and an additive for cleaving fusarium toxins comprising at least one polypeptide variant and optionally at least one adjuvant; the invention also relates to the use of said polypeptide variants or additives for hydrolytically cleaving at least one fusarium toxin, and to a method for hydrolytically cleaving at least one fusarium toxin.

One bacterial strain, designated HC1M1C21T, was isolated from human faeces and analyzed using phylogenetic, morphologic and biochemical approaches. Phylogenetic analyses based on 16S rRNA sequences and a set of 92 bacterial core genes indicated that this strain belongs to the Lachnospiraceae family and clusters near Pilosibacter fragilis (96.9% 16S rRNA sequence identity). HC1M1C21T has a DNA G+C content of 48.7 mol%. This strain is anaerobic, Gram- stain-positive, non-motile and non-spore-forming. HC1M1C21T cells appear as single rods or chained rods with tapered ends. Optimal growth was observed at 37°C, at pH between 5.5 and 6.5 and at salinity below 10 g / L. HC1M1C21T is a potent butyrate producer. The invention pertains to a new bacterial strain that produces butyrate and several independent factors with anti-inflammatory properties.

The invention relates to the technical field of biology, and particularly discloses a recombinant humanized II-type collagen biological scaffold and application thereof in cartilage repair. The recombinant humanized II-type collagen biological scaffold is formed by freezing and drying a polypeptide solution, and the amino acid sequence of polypeptide comprises n repetitive units, the repetitive unit comprises any one of the following amino acid sequences (1)-(3) or a variant sequence thereof: (1) an amino acid sequence as shown in SEQ ID NO.1; (2) an amino acid sequence having at least 50%-99% sequence identity with the amino acid sequence as shown in SEQ ID NO.1; (3) a variant sequence obtained by performing mutation of one or more amino acid residues on the amino acid sequence as shown in SEQ ID NO.1; wherein n is an integer greater than or equal to 1. The biological scaffold disclosed by the invention does not contain a cross-linking agent and an organic solvent, has high biocompatibility and can quickly repair cartilage tissues.

Methods for treating a mucopolysaccharidosis III (MPS III), also known as Sanfilippo syndrome, in a patient in need thereof are provided. In one aspect, the method comprises administering to the patient an effective amount of a polypeptide comprising human IL-1Ra, or a sequence having at last 85% sequence identity to the human IL-1Ra.

This invention provides a LYTACA polypeptide complex (sRD-Lytaca) targeting the degradation of soluble IL-17RD (sIL-17RD), its preparation method, and its applications. This polypeptide complex is formed by the self-assembly of the sIL-17RD-binding peptide sRDL and the scavenger receptor-binding peptide SRAL after Nap-FF modification and mixing. sRDL can be conjugated with fluorescently labeled molecules to prepare detection reagents for the detection of sIL-17RD. This invention also provides a variant with at least 80% sequence identity with sRDL and retaining binding ability, and pharmaceutical compositions containing sRDL and / or sRD-Lytaca. This invention provides a new technical means for the prevention and treatment of osteoarthritis and diseases related to sIL-17RD protein (such as rheumatoid arthritis).

The invention belongs to the technical field of biology, and particularly relates to a kok-saghyz natural rubber high-yield gene SCL190 and application thereof. The invention provides a nucleic acid molecule which comprises any one of the following nucleotide sequences: a nucleotide sequence as shown in SEQ ID NO: 1; a nucleotide sequence having at least 90% sequence consistency with the nucleotide sequence as shown in SEQ ID NO: 1; a nucleotide sequence encoding the amino acid sequence represented by SEQ ID NO: 2; a nucleotide sequence encoding an amino acid sequence having at least 90% sequence identity with the amino acid sequence as shown in SEQ ID NO: 2; wherein the nucleic acid molecule is capable of imparting higher root biomass and natural rubber content to kok-saghyz in which the nucleic acid molecule is overexpressed. The invention provides a new gene resource and method for cultivating a new variety of high-yield rubber kok-saghyz.

The present invention provides a novel luminescence-related gene (nucleic acid, expression vector) capable of providing a higher luminescence ability for an organism (particularly a plant) compared to a known luminescence-related gene. Provided is a nucleic acid comprising at least one nucleotide sequence selected from the group consisting of: a nucleotide sequence encoding a protein comprising an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence having a sequence identity of 90% or more to the sequence represented by SEQ ID NO: 1; a nucleotide sequence encoding a protein comprising: an amino acid sequence represented by SEQ ID NO: 2 or 3, or an amino acid sequence having 90% or more sequence identity with the sequence represented by SEQ ID NO: 2 or 3; a nucleotide sequence encoding a protein comprising: an amino acid sequence shown in SEQ ID NO: 4 or 5, or an amino acid sequence having 90% or more sequence identity with the sequence shown in SEQ ID NO: 4 or 5; and a nucleotide sequence encoding a protein comprising the amino acid sequence shown in SEQ ID NO: 6, or an amino acid sequence having 90% or more sequence identity with the sequence shown in SEQ ID NO: 6.

This invention relates to the field of biotechnology, specifically disclosing a novel polypeptide, recombinant XIX type humanized collagen, and their applications. This invention provides a novel polypeptide with good cell adhesion activity and the ability to promote cell proliferation. The amino acid sequence of the polypeptide comprises n repeating units; each repeating unit comprises any one of the following (1)-(3) amino acid sequences or their variants: (1) the amino acid sequence shown in SEQ ID NO.1; (2) an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO.1; (3) a variant sequence obtained by mutating one or more amino acid residues of the amino acid sequence shown in SEQ ID NO.1; wherein n ≥ 1 and is an integer. The polypeptide of this invention can be used in various fields such as promoting skin barrier repair, wound healing, and epidermal renewal.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The present invention relates to fusarium toxin cleavage polypeptide variants of a fusarium toxin carboxylesterase of SEQ ID No. 46 wherein said polypeptide variants each have an amino acid sequence shortened by 47 amino acids at the N-terminus and said amino acid sequence has a sequence identity of at least 70%, preferably 80%, particularly preferably 100%, to the amino acid sequence segments 48-540 of SEQ ID No. 46, i.e. SEQ ID No. 1; and isolated polynucleotides encoding the polypeptide variants; and an additive for cleaving fusarium toxins comprising at least one polypeptide variant and optionally at least one adjuvant; the invention also relates to the use of said polypeptide variants or additives for hydrolytically cleaving at least one fusarium toxin, and to a method for hydrolytically cleaving at least one fusarium toxin.

The present invention provides a polypeptide that specifically recognizes structurally abnormal proteins generated in mammals due to misfolding or the like, and an agent for detecting or reducing structurally abnormal proteins that uses the polypeptide. The present invention relates to an agent for detecting structurally abnormal proteins, comprising as an active ingredient a polypeptide having structurally abnormal proteins-binding site which is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO:2, or a polypeptide consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence and having binding activity to structurally abnormal proteins, and an agent for reducing structurally abnormal proteins comprising as an active ingredient a polypeptide containing the structurally abnormal protein binding site and a ubiquitin ligase active site.